Development of novel benzo[ d ][1,2,3]triazole-acetohydrazone derivatives as potential therapeutic agents: synthesis, SAR study, inhibition of carbohydrate metabolism enzymes, and aldose reductase supported by molecular modelling simulation
). Consequently, compound 11 holds promise as a lead molecule for developing novel therapeutic agents targeting α-amylase, α-glucosidase, and aldose reductase for diabetes management. Furthermore, molecular docking and molecular dynamics simulations (100 ns) elucidated stable interactions between compound 11 and the catalytic pockets of both α-amylase and α-glucosidase, primarily mediated by hydrogen bonding and hydrophobic interactions. The ADME analysis revealed an acceptable physicochemical profile, characterized by good aqueous solubility and a minimal predicted risk of CYP-mediated drug-drug interaction. Finally, these findings indicate that benzotriazole derivative 11 may serve as a promising scaffold for further optimization toward a multi-target anti-diabetic drug development agent.
Authors
- Mohga Basseem (ORCID: https://orcid.org/0000-0002-1333-5016)
- Ahmed Ragab (ORCID: https://orcid.org/0000-0001-8542-7465)
- Wael M. Aboulthana (ORCID: https://orcid.org/0000-0002-4848-0731)
- Mohamed H. El-Naggar (ORCID: https://orcid.org/0000-0001-8799-0235)
- Ahmed T. Elhendawy (ORCID: https://orcid.org/0009-0003-8815-2542)
- Mohamed E. Belasy
Institutions
- Al-Azhar University (EG)
- University of Sharjah (AE)
- National Research Centre (EG)
- Galala University (EG)
- ElSewedy University of Technology (EG)
Publication Details
- Journal
- RSC Advances
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1039/d6ra06631c
- Primary Topic
- Natural Antidiabetic Agents Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00